From the first time we met Li Sun, we were hooked. Her deep passion, immense drive, relentless pursuit, and bold vision are qualities that we often look for in a founder. But she is a rare combination of all of those things. I have learnt a lot from working with her over the past 18 months and look forward to continuing this journey as the company comes out of stealth today.

Shennon Bio is building a microfluidic platform to study the functional interactions between immune cells at a single-cell level in a high throughput manner. Platforms like Shennon power the development of new therapies by removing existing bottlenecks in immunotherapy, and enabling novel approaches to study cell interactions at unprecedented selectivity and throughput. At scale, Shennon’s platform will enable the development of better T cell therapies not only for their internal programs, but also for the broader ecosystem.

We’ve had a front row seat as Li has gotten this company off the ground and built an impressive team of scientists, engineers, and advisors. The platform has surpassed our expectations in terms of selectivity, throughput, and time to build.

We couldn’t be happier to continue this journey with Li, the rest of the Shennon team, and our amazing coinvestors DCVC and Foundation Capital. Come join this mission driven team that is making an impact in developing new therapies against cancer.